AV 1980R
Alternative Names: AV-1980R; Tau-Recom-vaccineLatest Information Update: 28 Dec 2025
At a glance
- Originator Flinders University; Institute for Molecular Medicine; University of California at Irvine
- Developer Capo Therapeutics
- Class Alzheimer vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (IM)
- 11 Feb 2025 US FDA approves an IND application for Alzheimer's disease (Nuravax pipeline, February 2025)
- 22 Dec 2023 Nuravax plans to file an IND application with the US FDA for Alzheimer's disease (Prevention) in 2023